Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells

Shouheng Lin(Chinese Academy of Sciences), Yao Yao(Dalian Medical University), Baiheng Li(Chinese Academy of Sciences), Duanqing Pei(Westlake University), Shuzhong Cui(Guangzhou Medical University), Youguo Long(Chinese Academy of Sciences), Suna Wang(Liaocheng University), Qiting Wu(Chinese Academy of Sciences), Yangqiu Li(Jinan University), Diwei Zheng(Wuhan University), Zhesheng Wen(Sun Yat-sen University), Wei Wei(Institute of Process Engineering), Peng Li(Chinese Academy of Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xiaofang Sun(Third Affiliated Hospital of Guangzhou Medical University), Simiao Lin(Chinese Academy of Sciences), Lin Cheng(Chinese Academy of Sciences), Guohua Huang(Nanfang Hospital), Jiang Lv(Chinese Academy of Sciences), Xuchao Zhang(Guangdong General Hospital), Pentao Liu(Hong Kong Science and Technology Parks Corporation)
Oncogene
January 15, 2021
10.1038/s41388-020-01605-4
Cited by 82

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k